What do systematic reviews say?

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.67 [0.96, 2.88]
  2 studies · 80 participants
  Low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 154 participants
  Very low

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 543 participants
  Very low

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

It is very uncertain whether summary of findings table ‐ Intralesional classical… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 13.84 [0.87, 219.76]
  1 study · 231 participants
  Very low

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

• Interventions for hand eczema 2019 · Cochrane Headline outcomes only
  RR 1.88 [0.88, 3.99]
  1 study · 34 participants
  Moderate

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

• Interventions for hand eczema 2019 · Cochrane Headline outcomes only
  RR 1.25 [0.69, 2.27]
  1 study · 34 participants
  Moderate

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).

• Interventions for hand eczema 2019 · Cochrane Headline outcomes only
  RR 1.22 [0.8, 1.86]
  1 study · 55 participants
  Moderate

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

• Interventions for hand eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Moderate

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 10 participants
  GRADE not reported

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

The review found no eligible studies for this question.

• Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found